These results open up alternative avenues for overcoming imatinib resistance, such as using USP14 and UCHL5 inhibitors as single agents or combined with imatinib in the treatment of T315I mutant CML patients. This evidence concerns the gene USP14 and chronic myelogenous leukemia, BCR-ABL1 positive.